• 1
    Putnam JJ. Cases of myxoedema and acromegalia treated with benefit by sheep's thyroids. Am J Med Sci 1893; 106: 125148.
  • 2
    Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805875.
  • 3
    Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59: 151184.
  • 4
    National Institutes of Health: NIH Consensus Development Conference Statement, Health Implications of Obesity. Ann Int Med 1985; 103: 19731977.
  • 5
    National Institutes of Health, National Heart, Blood and Lung Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res 1998; 6 (Suppl 2): S51S209.
  • 6
    Li Z, Maglione M, Tu W et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532546.
  • 7
    Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393403.
  • 8
    Rothman RB. Treatment of obesity with “combination” pharmacotherapy. Am J Ther, in press.
  • 9
    Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001; 2: 199211.
  • 10
    Wadden TA, Berkowitz RI, Womble LG et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 8: 431437.
  • 11
    Aydin N, Topsever P, Kaya A et al. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med 2004; 202: 173180.
  • 12
    Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004; 30: 159167.
  • 13
    Kaya A, Aydin N, Topsever P et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004; 58: 582587.
  • 14
    Haddock CK, Poston WS, Foreyt JP, DiBartolomeo JJ, Warner PO. Effectiveness of Medifast supplements combined with obesity pharmacotherapy: a clinical program evaluation. Eat Weight Disord 2008; 13: 95101.
  • 15
    Frank A. The long-term management of obesity with continuing pharmacotherapy. Obes Res 2004; 12: 18211827.
  • 16
    Weintraub M, Sundaresan PR, Schuster B et al. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin Pharmacol Ther 1992; 51: 608614.
  • 17
    Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther 2006; 109: 325338.
  • 18
    Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 1998; 3: 271280.
  • 19
    American Society of Bariatric Physicians. <http:www.asbp.orgsiterun_dataabout_asbpnews.phpq 770d63b79fe73fb00d7277f0b49285c0>. Accessed 11 November 2008.
  • 20
    Tilley BC, Alarcon GS, Heyse SP et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995; 122: 8189.
  • 21
    Volanen I, Kallio K, Saarinen M et al. Arterial intima-media thickness in 13-year-old adolescents and previous antichlamydial antimicrobial use: a retrospective follow-up study. Pediatrics 2008; 122: e675e681.
  • 22
    Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 3445.
  • 23
    Snow V, Barry P, Fihn SD et al. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004; 141: 562567.